Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

NCT01235598 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

OTHER: Placebo
BIOLOGICAL: Certolizumab Pegol (CZP) 200 mg
BIOLOGICAL: Certolizumab Pegol (CZP) 400 mg

Sponsor

UCB Pharma